SHANGHAI, Jan. 5, 2015 /PRNewswire/ -- WuXi PharmaTech stated today that a recent news report regarding purported FDA communication with a company named Novacyl Wuxi Pharmaceutical does not relate to WuXi PharmaTech.
Ron Aldridge
Director of Investor Relations
WuXi PharmaTech
+1 201-585-2048
+1 952-594-0148 (U.S.)
SOURCE WuXi PharmaTech
Share this article